Abstract: Simoctocog alfa (human-cl rhFVIII, Nuwiq ® ) is a 4th generation recombinant FVIII (rFVIII), without chemical modification or fusion with any other protein/fragment. Nuwiq ® is produced in a human embryonic kidney cell line (HEK293F), which ensures human-specific post-translational protein processing. Nuwiq ® was evaluated in seven prospective clinical studies in 201 adult and pediatric previously treated patients (PTPs) with severe hemophilia A. The NuProtect study in 110 previously untreated patients (PUPs) is ongoing. The mean half-life of Nuwiq ® was 15.1-17.1 h in PTP studies with adults and adolescents, and 12.5 h in children aged 2-12 years. Clinical trials in PTPs demonstrated the efficacy and safety of Nuwiq ® in the prevention and treatment of bleeds and as surgical prophylaxis. In the NuPreviq study of pharmacokinetic (PK)-guided personalized prophylaxis in 66 adult PTPs, 83% of patients had no spontaneous bleeds during 6 months of personalized prophylaxis and 57% were treated ⩽2 per week. No FVIII inhibitors were detected in PTPs after treatment with 43,267 injections and >80 million IU of Nuwiq ® . Interim data for 66 PUPs with ⩾20 exposure days to Nuwiq ® in NuProtect demonstrated a low cumulative high-titer inhibitor rate of 12.8% [actual incidence 12.1% (8/66)] and convincing efficacy and safety.
Introduction
Hemophilia A is treated by infusion of exogenous plasma-derived FVIII (pdFVIII) or recombinant FVIII (rFVIII), either prophylactically to prevent bleeds or as on-demand treatment after a bleed has occurred. 1, 2 Concerns about virus transmission from blood products have largely been ameliorated by integrating multiple viral inactivation and attenuation steps into the manufacturing process of pdFVIII products and the development of rFVIII products. [3] [4] [5] Since the introduction of the first-generation rFVIII produced in Chinese hamster ovary (CHO) cells in the early 1990s, there have been incremental improvements in rFVIII production and formulations, particularly in relation to the elimination of additives from animal/human sources and virus removal/inactivation. 4 The newer products were classified as 2nd and 3rd generation rFVIII products, and were derived from CHO and baby hamster kidney (BHK) cell lines. More recently, 4th generation products produced in human cell lines (HEK293F) have become available for the treatment of hemophilia A. [5] [6] [7] Primary prophylaxis has emerged as the standard of care for maintaining hemostasis and preserving joint function in children with severe hemophilia A. [8] [9] [10] There is also strong evidence for the benefits of prophylaxis (termed 'secondary') versus on-demand treatment in adults with severe hemophilia A. [11] [12] [13] [14] However, a 'one size fits all' approach to prophylaxis is not ideal, as this potentially leads to over-treatment in some individuals and undertreatment in others. Furthermore, a generic plan fails to take into account a patient's lifestyle and personal preferences. 15 Personalized, patienttailored prophylaxis based on pharmacokinetic (PK) data has the potential to optimize patient care and enable fewer infusions by matching the dosing regimen to the PK of each patient to ensure that all patients achieve a predetermined FVIII trough level and protection from bleeding. [15] [16] [17] [18] [19] [20] The development of neutralizing alloantibody inhibitors to FVIII replacement therapy, which neutralize the coagulation effects of FVIII replacement therapy, is generally considered the most serious complication in the current treatment of hemophilia A patients in economically developed countries due to major adverse implications for bleeding rates, morbidity, mortality, quality of life, and treatment costs. [21] [22] [23] [24] Inhibitors are estimated to develop in ~35% of previously untreated patients (PUPs) 25, 26 and 1% of previously treated patients (PTPs). 27 Inhibitor development is mediated by a complex interaction of unmodifiable host-related factors, such as hemophilia severity, family history, ethnicity, and F8 genotype, and potentially modifiable treatment-related factors, such as treatment intensity, FVIII dose, treatment regimen, and product type. 25, 26, 28, 29 Inhibitors can arise in patients with hemophilia A at any time throughout life with a bimodal risk, with peak incidence in early childhood [after a median of ~15 exposure days (EDs)] and a smaller peak in old age. 30, 31 Intensive treatment, for example for surgical procedures, has been shown to be a risk factor for FVIII inhibitor development in PTPs. 30, 32 Simoctocog alfa (human-cl rhFVIII, Nuwiq ® ; Octapharma AG, Switzerland) is a 4th generation rFVIII, without chemical modification or fusion with any other protein/fragment, produced in a human cell line. 6, [33] [34] [35] [36] The purification process involves 10 stages: one centrifugation, two filtration, five chromatography, and two dedicated pathogen clearance steps (solvent/detergent treatment and 20 nm nanofiltration). 37 The purification process ensures a virus-free product, and effectively removes process-related (proteins and DNA) and product-related (ratio active/inactive FVIII) impurities. 37 The production of Nuwiq ® in a human cell line results in human-specific post-translational protein processing, such as glycosylation and sulfation, which closely mimic those of endogenous FVIII. 34, 35, 38 Glycosylation alters the structural, functional, and immunogenic properties of a protein 7, 39 and the presence of glycans of nonhuman origin may have immunogenic potential. 40 Nuwiq ® has a glycosylation pattern similar to that of pdFVIII and is devoid of potentially antigenic, nonhuman glycan epitopes that are present in rFVIII products derived from hamster cell lines, and, thus, may be less immunogenic. 35, 41, 42 Sulfated residues play an important role in FVIII activation in the coagulation pathway and in the interaction between FVIII and von Willebrand factor (VWF). 7, 43 In human plasma, FVIII is noncovalently bound to VWF: a larger carrier protein that stabilizes FVIII by preventing proteolytic degradation and considerably prolongs FVIII survival. 38, 44 Sulfation of tyrosine 1680 impacts significantly on the VWF-binding affinity to FVIII and, consequently, on FVIII stability. 38, 45 It has been suggested that bound VWF acts as an immune modulating chaperone molecule for FVIII, reducing the immunogenicity of therapeutic FVIII. 46 Nuwiq ® is fully sulfated at all tyrosine binding sites, including tyrosine 1680, 35 and has a high binding affinity for VWF. 34 These properties suggest that Nuwiq ® might be less likely to induce the development of alloantibody inhibitors to FVIII, and have an extended circulating half-life in vivo compared with hamster cell line-derived rFVIII products.
Here, we describe key findings from prospective clinical trials in PTPs and PUPs with severe hemophilia A treated with Nuwiq ® as part of the GENA clinical trial program.
Overview of the GENA clinical trial program
The GENA clinical trial program for Nuwiq ® was developed with consideration of European Medicines Agency (EMA) guidelines 47 and after discussion with the US Food and Drug Administration (FDA). Five pre-registration clinical studies in PTPs were conducted in Europe and the USA: GENA-01, GENA-08, GENA-03, GENA-09, and its extension GENA-04. Studies GENA-01, 48 GENA-08, 48, 49 and GENA-03 50 were multinational pivotal studies (Table 1) . Data relating to surgical prophylaxis and safety from supportive studies (GENA-09/GENA-04) are also described here. GENA-09 was a 20 a study of PK-guided personalized prophylaxis in 66 adult PTPs (Table 1 ). In total, 201 PTPs (190 individuals) were enrolled across the seven PTP studies. 7, 20, 51 All seven PTP studies enrolled patients with severe hemophilia A, who had been previously treated (⩾150 EDs in patients ⩾12 years of age, ⩾50 EDs in patients <12 years of age). All patients were to be treated for at least 6 months and at least 50 EDs. Identical objective measures were used to assess prophylactic efficacy, hemostatic efficacy of on-demand (and breakthrough) bleeds, and surgical prophylaxis across all studies. The safety variables were practically identical across all studies. Key laboratory parameters were measured in the same certified central laboratory using the same validated methods. Plasma FVIII:C activity assays were used for PK assessment, and activity was measured by both a onestage coagulation and a chromogenic assay (indirectly measuring FVIII activity through its ability to generate factor Xa). Inhibitory antibodies were measured by the Bethesda assay (Nijmegen modification) method, as suggested by the EMA. 47, 53 An inhibitor was defined as an inhibitor titer ⩾0.6 (⩾0.6 to <5 BU [Bethesda units]/mL for a 'low titer' inhibitor and ⩾5 BU/mL for a 'high-titer' inhibitor). 
Clinical data in PTPs
Half-life The half-life of Nuwiq ® was assessed in 20 adults and two adolescents (N = 22) in GENA-01, 66 adults in NuPreviq and 26 children aged 2-12 years in GENA-03 (N = 13 aged 2-5 years and N = 13 aged 6-12 years) ( Table 2) . 20, 50, 52 In GENA-01 and GENA-03, half-life of a 50 IU/kg infusion of Nuwiq ® was calculated using a noncompartmental PK model. In the NuPreviq personalized prophylaxis study, half-life of a 60 ± 5 IU/kg infusion of Nuwiq ® was calculated using a one-or two-compartment PK model (as individually appropriate); a non-compartmental model was chosen in cases of uncertainty. The FVIII PK profile (one-stage assay) was best described by a two-compartment PK model for 36 (54.5%) patients, and by a one-compartment model for 23 (34.8%) patients. For the remaining seven patients (10.6%), a non-compartment model was used as neither a two-nor a onecompartment model appeared to be appropriate.
The mean ± SD half-life (one-stage assay) of Nuwiq ® in adults and adolescents was 17.1 ± 11.2 h and 15.1 ± 4.7 h in the GENA-01 and NuPreviq studies, respectively (Table 2 ). In GENA-03, 50 the mean ± SD half-life (one-stage assay) of Nuwiq ® was 11.9 ± 5.4 h in younger children (2-5 years), 13.1 ± 2.6 h in older children (6-12 years), and 12.5 ± 4.2 h overall ( Table  2 ). The shorter half-life in children compared with adults is well documented for rFVIII products, and may result from higher plasma volumes per unit weight in children compared with adults. 56, 57 Across the studies, half-life was shorter when using the chromogenic compared with the one-stage assay (Table 2 ).
An international comparative field study assessed the performance of one-stage and chromogenic assays in measuring FVIII activity of Nuwiq ® in routine clinical practice. 58 Data for Nuwiq ® and Advate ® , a hamster cell line-derived rFVIII, from 49 laboratories in nine countries were analyzed. Mean absolute FVIII:C was comparable for both products at all concentrations and for both assays, with interproduct ratios (Nuwiq ® :Advate ® ) of 1.02-1.13. Chromogenic to one-stage ratios based on overall means ranged from 0.99 to 1.17 for Nuwiq ® , and from 1.01 to 1.17 for Advate ® , which indicates similarly higher FVIII:C with the chromogenic assay for both products. These data demonstrate that the FVIII:C of Nuwiq ® can be accurately measured using both one-stage and chromogenic assays in routine laboratory practice, without the need for a product-specific reference standard. The majority of laboratories use one-stage assays for monitoring in the clinical setting. 59 -9 months; including ⩾6 months of PK-guided personalized prophylaxis *Includes two adolescents aged 12-17 years. $ Study GENA-13 was an extension of study GENA-03; therefore, all of these patients participated in study GENA-03. ‡ A total of 11 patients had previously participated in GENA-01 or GENA-08. PTP, previously treated patient; ED, exposure day; PK pharmacokinetic, IVR, in vivo recovery.
Prevention of bleeds
Standard prophylaxis. The efficacy of standard prophylaxis with Nuwiq ® was assessed in pivotal studies of adults and children aged 2-12 years and in the GENA-13 extension study in children. [49] [50] [51] The recommended dose for prophylaxis was 30-40 IU FVIII/kg administered every other day in GENA-08 and every other day or three times per week in GENA-03 and GENA-13.
In GENA-08, the median (mean) annualized bleeding rates (ABRs) during Nuwiq ® prophylaxis were 0.9 (2.28) for all bleeds and 0 (1.16) for spontaneous bleeds (Table 3) . 49 For all joint bleeds (ankle, elbow, knee), the median (mean) ABR was 0 (1.14). The ABR (negative binomial regression estimate) during prophylaxis with Nuwiq ® in GENA-08 was 2.30 compared with 57.74 during on-demand treatment in GENA-01, which equates to a 96% lower ABR during prophylaxis. 48 The ABR for all joint bleeds was 1.15 during prophylaxis, compared with 35.26 during on-demand treatment, which equates to a 97% lower ABR for joint bleeds during prophylaxis. 48 In GENA-03, the median (mean) ABRs in children were 1.9 (4.12) for all bleeds and 0 (1.50) for spontaneous bleeds (Table 3) . 50 For all joint bleeds, median (mean) ABR was 0 (1.53). In six patients who had previously received on-demand treatment, a 97% reduction in mean ABR from 35.9 to 0.96 was observed.
A total of 49 children from GENA-03 continued Nuwiq ® prophylaxis in GENA-13 for a mean of 2.5 years. 51 The mean ± SD dose per prophylactic infusion was comparable between GENA-03 and GENA-13 (38.6 ± 6.7 and 38.6 ± 7.4 IU/kg, respectively). The median (mean) ABR was 1.72 (2.91) for all bleeds and 0.34 (0.67) for spontaneous bleeds (Table 3) . Younger children (2-5 years) had lower ABRs than children aged 6-12 years. For all joint bleeds, median (mean) ABR was 0.36 (0.85). ABRs were markedly reduced in GENA-13 versus GENA-03, especially for spontaneous bleeds in younger children, in whom a 71% reduction was observed (Figure 1 ). During 2.5 years of prophylaxis treatment, 45% of children had no spontaneous bleeds (Octapharma, data on file).
PK-guided personalized prophylaxis. PK-guided personalized prophylaxis with Nuwiq ® was assessed in the NuPreviq (GENA-21) study. 20 The study consisted of three phases: an initial PK evaluation phase; a 1-3 month standard prophylaxis treatment phase; and a 6-month PK-guided personalized prophylaxis phase.
The prophylactic dose and dosing interval recommended for the personalized prophylaxis phase were based on the analysis of individual PK data obtained using the one-stage assay at the initial evaluation. As patients with FVIII:C >1% experience fewer spontaneous bleeds and consequential damage, the main aim of prophylaxis is to keep the FVIII plasma level >1%. 15 The goal in NuPreviq was to determine the maximum regular prophylactic dosing interval that could be achieved with a single dose of not more than 60-80 IU/kg, while maintaining a trough FVIII:C level of ⩾1% and not exceeding a maximum plasma FVIII:C of 200%.
The majority of patients (62%, 41/66) received only on-demand treatment in the 6 months prior to the study. Prior mean ± SD ABRs were 38.9 ± 27.59, 45.6 ± 23.71, and 27.8 ± 30.33 for all patients, prior on-demand patients and prior prophylaxis patients (at least one dose of regular or irregular prophylactic treatment), respectively, during which the weekly doses were 34.3 ± 28.64, 21.1 ± 8.78, and 56.6 ± 36.19 IU/kg, respectively. Mean ± SD Hemophilia Joint Health Score was 41.4 ± 25.2 in patients who were previously treated on-demand, and 30.3 ± 24.3 in patients who received previous prophylaxis.
The median dosing interval during personalized prophylaxis was 3.5 days, with 57% of patients on ⩽2 weekly dosing. During personalized prophylaxis, 83% of patients had no spontaneous bleeds, and 74% had no bleeds of any type. Median (mean) ABRs during personalized prophylaxis were 0 (1.45) for all bleeds, 0 (0.79) for spontaneous bleeds, and 0 (0.91) for joint bleeds (Table 3) . Compared with the preceding standard prophylaxis regimen, median weekly prophylaxis dose was reduced by 7.2% from 100.0 to 92.8 IU/kg during the last 2 months of personalized prophylaxis.
In patients with available measurements, mean ± SD FVIII trough levels after 2, 4, and 6 months of personalized prophylaxis were 3.4% ± 4.0 (n = 19), 4.2% ± 7.0 (n = 24), and 2.7% ± 2.4 (n = 20), respectively. Thus, trough levels were consistent throughout personalized prophylaxis with Nuwiq ® and higher than the target level of 1%. In clinical practice, target FVIII trough levels can be set according to individual needs to provide greater bleed protection when needed (e.g. patients with high physical activity levels and/or with bleeding phenotype even at 1-5% troughs). A recent Delphi Consensus Statement recommended the use of different target plasma FVIII levels tailored to individual people with hemophilia A. 60 
Treatment of bleeds
The efficacy of Nuwiq ® in the treatment of bleeds was assessed in all three pivotal studies and the GENA-13 and NuPreviq studies. Efficacy was assessed during on-demand treatment in GENA-01 48 and in the treatment of breakthrough bleeds during prophylaxis in the other studies 20,48-51 (Table 4) . Efficacy was assessed as excellent, good, moderate or none at the end of each bleed according to predefined objective criteria (Table  4) , including the number of infusions and improvement in signs of bleeding and pain.
Efficacy of Nuwiq ® for on-demand treatment of bleeds or treatment of breakthrough bleeds during prophylaxis was assessed for 1530 bleeds across the five studies. The majority of the bleeds were as expected in the GENA-01 study, which was specifically designed to assess the efficacy of on-demand treatment. In GENA-01, efficacy in the treatment of bleeds was rated as excellent or good for 94.5% of 985 evaluated bleeds, with efficacy in 5.5% of bleeds rated as moderate. 48 The vast majority (97.2%) of bleeds were treated with 1 (91.4%) or 2 (5.8%) infusions. The mean ± SD number of infusions and dose per bleed were 1.1 ± 0.59 and 36.6 ± 27.64 IU/kg, respectively. . Estimated annualized bleeding rates (ABRs) (95% CIs) for spontaneous bleeds in the main pediatric study (GENA-03) and its long-term extension (GENA-13). Only patients enrolled in both studies were considered. ABRs were estimated based on calculations using a negative binomial counting regression model and considering only the time under prophylaxis. BE, bleeding episode; LTE, long-term extension. Data from Klukowska and colleagues. 51 Across the prophylaxis studies, the majority of bleeds were treated successfully with one or two infusions (Table 4) .
Surgical prophylaxis
Across all seven GENA studies, 36 patients aged 3-55 years received surgical prophylaxis with Nuwiq ® for 60 surgeries (28 major and 32 minor), and efficacy was evaluated for 52 surgeries (25 major and 27 minor). 61 The Across the seven studies, 12 adverse drug reactions (ADRs) occurred once each in eight patients. Ten ADRs were mild, and two were severe (malaise, dizziness). Both severe events occurred in the same patient during the standard prophylaxis phase of the NuPreviq study and resolved without sequelae. One ADR, mild pyrexia in a child in GENA-13, was classified as serious because the patient was hospitalized. The pyrexia resolved without sequelae. The remaining nine mild, non-serious ADRs were: vertigo, dry mouth, paresthesia, and injection site inflammation (all in the same GENA-08 patient during the first infusion); injection site pain (GENA-08); back pain (GENA-03); headache (GENA-03); dyspnea (GENA-13); and FVIII antibody positive (non-neutralizing) (GENA-04).
A non-neutralizing anti-FVIII antibody was detected in one adult patient in GENA-04 (completion visit) that was judged to be related to treatment. The sample was tested by the central laboratory at eight dilutions. The result was positive only at dilution factor 1, and the antibody titer was very low (0.34). Inhibitory activity, as measured by the modified Bethesda assay, was not detected in this patient. The antibody was undetectable at a subsequent examination. Efficacy in this patient did not seem to be affected, as he had no breakthrough bleeds during the study, and, on the day the positive anti-FVIII antibody was detected, his in vivo recovery was unaffected.
Clinical trial data in PUPs
An interim analysis was performed on data from 66 PUPs who had been treated with Nuwiq ® for at least 20 EDs, 55 the time by which most inhibitors develop. 25 Of the nine surgical procedures during inhibitorfree periods with available efficacy assessments, efficacy was rated as 'excellent' or 'good' in eight procedures and 'moderate' in one procedure.
Three patients experienced adverse events (AEs) assessed to be related to treatment (other than inhibitor development): one experienced mild fever; one experienced mild allergic reactions after three consecutive Nuwiq ® administrations (his other 105 infusions were without complication); and the third patient developed a rash, which, although mild, was considered serious due to hospitalization. He continued treatment until completion of the study with no other related AEs. No venous or arterial thromboembolic complications or severe allergic reactions were recorded.
Discussion
Use of a human cell line and state-of-the-art production and purification processes has resulted in a 4th generation rFVIII with human-specific post-translational protein processing that is virusfree and of high purity. The NuPreviq study has shown that individual PK-guided personalized prophylaxis with Nuwiq ® in adult PTPs provides excellent bleed protection, with 83% of patients free from spontaneous bleeds during 6 months of treatment and 74% of patients having no bleeds of any type; 57% of patients were on ⩽2 weekly dosing, and there was a 7.2% reduction in median dose compared with standard prophylaxis. 20 The results of the NuPreviq study compare favorably with published data for other rFVIII products, although differences in study designs and patient populations prevent direct comparison of results from different studies. In studies of similar duration (~6 months), the percentage of patients with no bleeds was 39.6% for twice weekly PEGylated full-length rFVIII derived from CHO cells, 64 43% for twice or three times weekly single-chain rFVIII derived from CHO cells, 65 and 74% during personalized prophylaxis with Nuwiq ® , which is derived from human HEK293F cells. 20 In longer studies, 45.3% of patients treated with individualized rFVIII-Fc (67% ⩽2 infusions per week) derived from the human HEK293F cell line had no bleeds over ~8 months, 19, 66 26 .5% of patients treated PK-tailored with full-length rFVIII derived from CHO cells had no bleeds over 1 year, 17 and 27% of patients treated with full-length rFVIII derived from BHK cells had no bleeds over 1 year. 67 The high percentage of patients with no bleeds during personalized prophylaxis with Nuwiq ® is reflected in the very low mean ABR of 1.45 (median 0). 20 Mean ABRs reported in other studies ranged from 1.9 to 4.9 and median ABRs ranged from 1.1 to 2.0. 17, 19, 64, 65, 67 In Italy, a modified NuPreviq approach that includes six sampling points and at-home sampling has been used successfully in routine clinical practice. 68 Low bleeding rates can also be achieved with Nuwiq ® in adults and children using a standard prophylaxis regimen. 49, 50 The results of 6-month studies compare favorably with published data for standard prophylaxis with other rFVIII products in PTPs, 11, 17, [72] [73] [74] [75] although, again, differences in study designs and patient populations limit direct comparisons between studies. In adult populations, the median ABR for all bleeds during standard prophylaxis was 0.9 (mean 2.28) for Nuwiq ®,49 median not reported (mean 5.3) for full-length rFVIII from CHO cells and 3.62 (mean 6.68) for B-domain-truncated rFVIII derived from CHO cells. 74, 75 In children treated with standard prophylaxis, the median ABR was 1.9 (mean 4.12) for Nuwiq ® in children aged 2-12 years of age 50 and 3.02 (mean 5.33) for B-domain-truncated rFVIII derived from CHO cells in children aged 0-11 years. 76 Median ABRs for full-length rFVIII from CHO cells were 4.0 in children aged 1-6 years, 77 and 5.2 in children aged 7-12 years. 78 Interim data from the NuProtect study show that PUPs treated with Nuwiq ® for ⩾20 EDs had a cumulative inhibitor rate of 20.8% (12.8% hightiter inhibitors). 55 In the 'Study on Inhibitors in Plasma-Product Exposed Toddlers' (SIPPET), 251 PUPs randomized to pdFVIII/VWF or hamster-cell-derived rFVIII treatment were evaluated. 26 Patients were to be treated for 50 consecutive EDs or 3 years or until inhibitor development was confirmed by a central laboratory. Of the 251 PUPs, 216 (86%) completed the trial according to the study protocol. The cumulative incidence of inhibitors for pdFVIII/VWF was 26.8% (18.6% high-titer) and 44.5% (28.4% high-titer) for rFVIII. 26 A post hoc analysis of SIPPET data reported that F8 genotype had an important influence on the journals.sagepub.com/home/tah 11 risk of inhibitor development with rFVIII compared with pdFVIII/VWF. 79 Among patients classified at high risk for inhibitor development (null F8 mutations), the cumulative incidence of inhibitors was 31% in 101 patients treated with pdFVIII/VWF, and 47% in 96 patients treated with rFVIII. In contrast, among patients classified as low risk (non-null F8 mutations), no inhibitors developed in 16 patients receiving pdFVIII/VWF treatment, whereas the cumulative incidence of inhibitors was 43% in 22 patients treated with rFVIII. Based on these findings, a post hoc analysis of the interim data from the NuProtect study was performed to investigate the influence of F8 genotype on inhibitor development. 63 Of the 47 patients with null F8 mutations, 12 developed FVIII inhibitors (cumulative incidence 26.7%), whereas none of 11 patients with non-null F8 mutations developed inhibitors with Nuwiq ® .
These F8 genotype results suggest that Nuwiq ® appears to follow the pattern exhibited by pdFVIII/ VWF concentrates rather than that of the hamster-cell derived rFVIII concentrates. Nuwiq ® was designed with the aim of reducing inhibitor development by replicating the native human FVIII protein and avoiding/minimizing potential immunogenic elements of rFVIII produced in hamster cell lines. [33] [34] [35] Nuwiq ® is fully sulfated at tyrosine 1680, which is critical for FVIII binding to VWF. 35 In functional studies, Nuwiq ® had a higher VWF binding compared with hamster-cell derived rFVIII products tested, 34 which suggests that it can efficiently bind to the endogenous VWF and that this may contribute to its low immunogenicity when interacting with antigen-presenting cells in the immune system.
In conclusion, comprehensive data from the GENA clinical trial program demonstrate the excellent efficacy and safety of Nuwiq ® in PTPs and PUPs. Nuwiq ® represents an important advance in the prevention and treatment of bleeds in patients with severe hemophilia A and can facilitate personalized treatment and reduce the risk of inhibitors.
